All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Protection by Vaccines and Previous Infection Against the Omicron Variant of Severe Acute Respiratory Syndrome Coronavirus 2

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F60077344%3A_____%2F22%3A00558712" target="_blank" >RIV/60077344:_____/22:00558712 - isvavai.cz</a>

  • Alternative codes found

    RIV/67985807:_____/22:00558712 RIV/67985556:_____/22:00558712 RIV/60076658:12310/22:43904748 RIV/00216208:11110/22:10443421 and 2 more

  • Result on the web

    <a href="https://doi.org/10.1093/infdis/jiac161" target="_blank" >https://doi.org/10.1093/infdis/jiac161</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.1093/infdis/jiac161" target="_blank" >10.1093/infdis/jiac161</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    Protection by Vaccines and Previous Infection Against the Omicron Variant of Severe Acute Respiratory Syndrome Coronavirus 2

  • Original language description

    The Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) evades immunity conferred by vaccines and previous infections. We used a Cox proportional hazards model and a logistic regression on individual-level population-wide data from the Czech Republic to estimate risks of infection and hospitalization, including severe states. A recent (≤2 months) full vaccination reached vaccine effectiveness (VE) of 43% (95% confidence interval [CI], 42%–44%) against infection by Omicron compared to 73% (95% CI, 72%–74%) against Delta. A recent booster increased VE to 56% (95% CI, 55%–56%) against Omicron infection compared to 90% (95% CI, 90%–91%) for Delta. The VE against Omicron hospitalization of a recent full vaccination was 45% (95% 95% CI, 29%–57%), with a recent booster 87% (95% CI, 84%–88%). The VE against the need for oxygen therapy due to Omicron was 57% (95% CI, 32%–72%) for recent vaccination, 90% (95% CI, 87%–92%) for a recent booster. Postinfection protection against Omicron hospitalization declined from 68% (95% CI, 68%–69%) at ≤6 months to 13% (95% CI, 11%–14%) at >6 months after a previous infection. The odds ratios for Omicron relative to Delta were 0.36 (95% CI, .34–.38) for hospitalization, 0.24 (95% CI, .22–.26) for oxygen, and 0.24 (95% CI, .21–.28) for intensive care unit admission. Recent vaccination still brings substantial protection against severe outcome for Omicron.

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database

  • CEP classification

  • OECD FORD branch

    30102 - Immunology

Result continuities

  • Project

  • Continuities

    I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Others

  • Publication year

    2022

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    Journal of Infectious Diseases

  • ISSN

    0022-1899

  • e-ISSN

    1537-6613

  • Volume of the periodical

    226

  • Issue of the periodical within the volume

    8

  • Country of publishing house

    GB - UNITED KINGDOM

  • Number of pages

    6

  • Pages from-to

    1385-1390

  • UT code for WoS article

    000805341600001

  • EID of the result in the Scopus database

    2-s2.0-85140144811